InflaRx (IFRX) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and pipeline focus

• Focuses on late-stage complement therapeutics, targeting C5a and C5aR signaling in immunodermatology.

• Lead monoclonal antibody, vilobelimab (Gohibic), is available in the US for severe COVID under emergency use and in late-stage development for pyoderma gangrenosum.

• INF904, an oral C5aR inhibitor, is advancing to phase II for hidradenitis suppurativa and chronic spontaneous urticaria.

• Key milestones include phase II study initiation for INF904 by year-end and interim readout for the PG phase III study next year.

• Selected for a large US government ARDS trial under the BARDA Just Breathe program.

Scientific rationale and therapeutic targeting

• C5a/C5aR is a central inflammatory mediator, distinct from upstream complement targets, and drives neutrophil and monocyte activation.

• Blocking C5a offers unique therapeutic benefits not achieved by C5 inhibitors, as shown in COVID studies.

• C5a targeting is relevant in neutrophilic skin diseases and allergic conditions, including chronic spontaneous urticaria.

• INF904 aims to address dosing and tissue penetration challenges observed with previous antibody approaches.

Commercialization and market challenges

• Gohibic's commercial uptake for COVID has been limited by lack of pre-launch activities, hospital stocking hurdles, and acute care logistics.

• Innovative warranty programs and increased KOL engagement are being used to drive adoption.

• Minimal investment is maintained to keep the drug available, with potential upside if market conditions improve.

• Strategic partnerships for commercialization have been explored but not realized due to market fatigue.